HKT-500 in Adult Patients With Osteoarthritis (OA) Knee Pain
A Randomized, Multicenter, Double-Blind, Placebo-Controlled, Four-Week Study to Assess the Efficacy and Safety of HKT-500 in Subjects With Pain Caused by Mild to Moderate Osteoarthritis of the Knee
Sponsor: Hisamitsu Pharmaceutical Co., Inc.
A PHASE3 clinical study on Osteoarthritis of the Knee, this trial is completed. The trial is conducted by Hisamitsu Pharmaceutical Co., Inc. and has accumulated 8 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.
Status Flow
Change History
8 versions recorded-
Sep 2025 — Present [monthly]
Completed PHASE3
-
Sep 2024 — Sep 2025 [monthly]
Completed PHASE3
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE3
-
Apr 2022 — Jul 2024 [monthly]
Completed PHASE3
-
Jan 2021 — Apr 2022 [monthly]
Completed PHASE3
▶ Show 3 earlier versions
-
Jun 2018 — Jan 2021 [monthly]
Completed PHASE3
-
Feb 2017 — Jun 2018 [monthly]
Completed PHASE3
-
Jan 2017 — Feb 2017 [monthly]
Completed PHASE3
First recorded
Sep 2007
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Hisamitsu Pharmaceutical Co., Inc.
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Albuquerque, United States , Anderson, United States , Arlington, United States , Austin, United States , Birmingham, United States , Bismarck, United States , Chandler, United States , Charlottesville, United States , Cincinnati, United States , Colorado Springs, United States and 24 more locations